Overall, it is recommended to perform annual biochemical testing (including plasma or urinary metanephrines and 3-methoxytyramine [3-MT], and CgA in metanephrine/3-MT-negative PGL) combined with imaging studies every 1-2 years, for early detection of tumor recurrence or metastatic disease. This evidence concerns the gene CGA and metastatic neoplasm.